Your browser doesn't support javascript.
loading
MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas.
Stopfer, Lauren E; Rettko, Nicholas J; Leddy, Owen; Mesfin, Joshua M; Brown, Eric; Winski, Shannon; Bryson, Bryan; Wells, James A; White, Forest M.
Affiliation
  • Stopfer LE; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Rettko NJ; Center for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Leddy O; Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158.
  • Mesfin JM; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Brown E; Center for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Winski S; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139.
  • Bryson B; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Wells JA; Pfizer Boulder Research & Development, Boulder, CO 8030.
  • White FM; Pfizer Boulder Research & Development, Boulder, CO 8030.
Proc Natl Acad Sci U S A ; 119(49): e2208900119, 2022 12 06.
Article in En | MEDLINE | ID: mdl-36454758
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mitogen-Activated Protein Kinase Kinases / Melanoma Limits: Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mitogen-Activated Protein Kinase Kinases / Melanoma Limits: Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2022 Type: Article